| Literature DB >> 35666914 |
Lin He1, Freideriki Michailidou2,3, Hailey L Gahlon2, Weibin Zeng4.
Abstract
Given the worldwide popularity of hair dyeing, there is an urgent need to understand the toxicities and risks associated with exposure to chemicals found in hair dye formulations. Hair dyes are categorized as oxidative and nonoxidative in terms of their chemical composition and ingredients. For several decades, the expert panel's Cosmetic Ingredient Review (CIR) has assessed the safety of many of the chemicals used in hair dyes; however, a comprehensive review of hair dye ingredients and the risk of exposure to hair dyeing has not been documented. Herein, we review the safety of the various chemicals in oxidative and nonoxidative hair dyes, toxicities associated with hair dyeing, and the carcinogenic risks related to hair dyeing. While many compounds are considered safe for users at the concentrations in hair dyes, there are conflicting data about a large number of hair dye formulations. The CIR expert panel has ratified a number of coloring ingredients for hair dyes and banned a series of chemicals as carcinogenic to animals and unsafe for this application. The use of these chemicals as raw materials for producing hair dyes may result in the synthesis of other contaminants with potential toxicities and increased risk of carcinogenesis. It is an open question whether personal or occupational hair dyeing increases the risk of cancer; however, in specific subpopulations, a positive association between hair dye use and cancer occurrence has been reported. To address this question, a better understanding of the chemical and mechanistic basis of the reported toxicities of hair dye mixtures and individual hair dye ingredients is needed. It is anticipated that in-depth chemical and systems toxicology studies harnessing modern and emerging techniques can shed light on this public health concern in the future.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35666914 PMCID: PMC9214764 DOI: 10.1021/acs.chemrestox.1c00427
Source DB: PubMed Journal: Chem Res Toxicol ISSN: 0893-228X Impact factor: 3.973
Category and Composition of Modern Hair Dyes
| dye category | hair coloring process | composition | hair dyeing type |
|---|---|---|---|
| temporary | nonoxidative | water-soluble acidic and basic dyes bearing azo or anthraquinone groups | deposition on hair |
| semipermanent | nonoxidative | acid and basic dyes bearing azo groups, anthraquinones, triphenylmethanes and nitro derivatives as chromophores | ionic interactions or van der Waals forces |
| permanent | oxidative | precursor agent, coupling agent and oxidizer | penetration into hair |
Figure 1Chemical structures of hair dye ingredients. Chemical structures of the following hair dye ingredients are shown: p-phenylenediamine 1 (PPD), N-monoacetyl-p-phenylenediamine 2 (MAPPD), N,N-diacetyl-p-phenylenediamine 3 (DAPPD), N-phenyl-p-phenylenediamine 4, N,N-bis(hydroxyethyl)-p-phenylenediamine 5, hydroxypropyl bis(N-hydroxyethyl-p-phenylenediamine) 6, 2-chloro-p-phenylenediamine 7, 4-methoxy-m-phenylenediamine 8, p-methylaminophenol 9, 2-methyl-5-hydroxyethylaminophenol 10, 2,4-diaminophenol 11, hydroquinone 12, t-butyl hydroquinone 13, toluene-2,5-diamine (CAS no: 95-70-5) 14, toluene-3,4-diamine 15, Disperse Blue 7 16, Disperse Violet 1 17, Disperse Yellow 3 18, Acid Violet 43 19, Basic Blue 99 20, HC Blue no. 2 21, HC Yellow no. 5 22, HC Red no. 7 23, 3-nitro-p-hydroxyethylaminophenol 24, 4-amino-3-nitrophenol 25, 4-amino-2-hydroxytoluene 26, 1-naphthol 27, resorcinol 28, o-phenylenediamine 29, 4-chloro-o-phenylenediamine 30, 4-aminobiphenyl 31, and di-n-butyl phthalate 32. Only the core chemical structures are shown. The sulfate or hydrochloride salts are omitted for simplicity.
Detailed Characteristics of Major Hair Dye Ingredientsa
| compound | year | maximum allowable concentration (%) | LD50 (mg/kg) | toxicity | carcinogenicity | ref |
|---|---|---|---|---|---|---|
| 1984 | ≤5 | 264 | reduced body weight; darkened thyroid glands; decreased serum iron concentration; delayed hypersensitivity; allergic contact dermatitis | no evidence | ( | |
| 1993 | ≤1.7 | 464–1000 | reduced body weight; degenerated seminiferous tubules; skeletal malformations; skin irritation | no evidence | ( | |
| hydroxypropyl bis( | NA | ≤0.4 | 2186 | reduced body weight, mean serum glucose and total protein levels; reproductive and developmental toxicity | no evidence | ( |
| 4-methoxy- | 1978 | NA | 400–500 | skin irritation; mutagenicity | animal carcinogenicity | ( |
| 2-chloro- | 1984 | ≤1.0 | NA | skin irritation; reduced body weight; ocular irritation | no evidence | ( |
| 2-methyl-5-hydroxyethylaminophenol | NA | ≤5 | 5700 | skin irritation; mutagenicity; allergic contact dermatitis | no evidence | ( |
| NA | ≤1 | NA | increased rate of formation of methemoglobin; skin irritation | no evidence | ( | |
| 2,4-diaminophenol | 1993 | ≤0.2 | 240 | skin irritation; severe ocular irritation; mutagenicity | no evidence | ( |
| hydroquinone | 1981 | ≤1 | 627–743 | nephrotoxicity; cytotoxicity; skin irritation; skin sensitization; skin depigmentation; mutagenicity | animal carcinogenicity | ( |
| 1981 | ≤0.1 | 480–800 | reduced body weights; mutagenicity | no evidence | ( | |
| toluene-2,5-diamine | 1984 | ≤4 | 98–102 | skin irritation; skin sensitization; ocular irritation; reproductive toxicity; skeletal malformation | no evidence | ( |
| toluene-3,4-diamine | 1984 | NA | NA | duodenal lesions; genotoxicity; skin sensitization | no evidence | ( |
| Disperse Blue 7 | 2002 | NA | NA | mutagenicity | no evidence | ( |
| Disperse Violet 1 | 1988 | ≤1 | NA | ocular irritation | no evidence | ( |
| Disperse Yellow 3 | 1992 | NA | NA | nephrotoxicity; chromosomal aberrations; allergic contact dermatitis | animal carcinogenicity | ( |
| Acid Violet 43 | 1984 | ≤1 | NA | no significant toxicity | no evidence | ( |
| Basic Blue 99 | 1992 | ≤2 | >2000 | skin irritation | no evidence | ( |
| HC Blue no. 2 | 1993 | ≤1.7 | 1250–5000 | mutagenicity | no evidence | ( |
| HC Yellow no. 5 | 2002 | ≤1.6 | 555.56 | skin irritation | no evidence | ( |
| HC Red no. 7 | 2005 | ≤1 | NA | skin sensitization; mutagenicity | no evidence | ( |
For chemical structures, refer to Figure .
The first yearly report by the Food and Drug Administration.
The oral LD50 in rats of aqueous solutions. Abbreviations: LD50, median lethal dose; NA, not assessed.
Figure 2Mechanism of toxicity induced by p-phenylenediamine. An increase in reactive oxygen species is associated with PPD 1-induced apoptosis. Dermal N-acetylation biotransforms PPD toward MAPPD 2 and DAPPD 3; at concentrations up to 250 μM, it is beneficial to the MAPPD formation, and at the concentration of 250–1000 μM, it is beneficial to the DAPPD formation. MAPPD and DAPPD fail to activate DCs or cause a positive LLNA response, which are considered the markers of extracorporeal and intracorporeal sensitizing potential of chemical compounds. PPD can induce DC activation after exposure to oxygen in air in vitro, and creates an LLNA response in vivo. The sensitizing PPD oxidation provides some effective immune stimulation that is associated with PPD-induced toxicity. Abbreviations: ROS, reactive oxygen species.
Hair Dye-Related Toxicity from a Case Report Study
| toxicity | study duration | sex | age | ingredients | exposure route | symptom timing | patch test concen-tration (%) | positive reaction | ref |
|---|---|---|---|---|---|---|---|---|---|
| ACD | 2015 | F | 50 | henna | hair dyeing | 4 d | 0.01 | 1+ | ( |
| ACD | 2005 | F | 50 | 3-nitro- | hair dyeing | 1 d | 1.00 | 1+ | ( |
| contact anaphylaxis | 2017 | F | 56 | Basic Blue 99 | hair dyeing | 10 min | 0.10 | 3+ | ( |
| ACD | 2009 | F | 47 | 4-amino-2-hydroxytoluene | hair dyeing | NA | 1.00 | 2+ | ( |
| ACD | 2018 | F | 43 | 1-naphthol | hair dyeing | 2 d | 1.00 | 3+ | ( |
| DLE | 2016 | F | 32 | hair dyeing | NA | NA | 2+ | ( | |
| angioedema | 2018 | F | 29 | hair dyeing | 1 d | 1.00 | 3+ | ( | |
| neck and facial swelling | 2016 | F | 15 | hair dyeing | 3 d | NA | 3+ | ( | |
| severe facial swelling | 2014 | F | 33 | hair dyeing | 2 d | NA | 4+ | ( | |
| hair loss | 2011 | F | 41 | hair dyeing | 1 d | 1.00 | 2+ | ( | |
| pneumothorax | 2011 | 2F | 19 ± 1 | consumption | NA | NA | NA | ( | |
| rhabdomyolysis | 2013 | M | 3 | consumption | 2 h | NA | NA | ( | |
| rhabdomyolysis | 2002–2006 | 8M + 2F | 23.2 ± 7.6 | consumption | NA | 0.95 | NA | ( |
Symptom timing indicates the duration from exposure to symptoms.
These studies describe more than one case, and the age is the mean value.
The positive reaction is calculated in terms of the patch test of corresponding ingredients at the patch test concentration. Abbreviations: F, female; M, male; NA, not assessed.
Studies Assessing the Association between Hair Dye Use and Carcinogenic Risk
| study | study type | publication year | original nation | cases/controls | carcinogenic risk | association analysis | ref |
|---|---|---|---|---|---|---|---|
| Gago-Dominguez | case-control study | 2001 | USA | 897/897 | bladder cancer | 2.1-fold ( | ( |
| Kogevinas | case-control study | 2006 | Spain | 152/166 | bladder cancer | OR, 0.80 (0.50–1.50) | ( |
| Thun | epidemiologic study | 1994 | USA | NA | bladder cancer | RR, 0.56 (0.32–0.99) | ( |
| breast cancer | RR, 0.95 (0.83–1.05) | ||||||
| non-Hodgkin’s lymphoma | RR, 0.95 (0.74–1.23) | ||||||
| Hodgkin’s lymphoma | RR, 0.55 (0.23–1.36) | ||||||
| multiple myeloma | RR, 1.05 (0.75–1.47) | ||||||
| Henley | comment | 2001 | USA | NA | bladder cancer | RR, 1.08 (0.84–1.38) | ( |
| Hartge | case-control study | 1982 | USA | 2982/5782 | bladder cancer | RR, 1.00 (0.90–1.20) | ( |
| Ros | case-control study | 2012 | The Netherlands | 1385/4754 | bladder cancer | OR, 0.87 (0.65–1.18) | ( |
| Koutros | case-control study | 2011 | USA | 61/102 | bladder cancer | OR, 3.30 (1.20–8.90) | ( |
| Gago-Dominguez | case-control study | 2003 | USA | 33/12 | bladder cancer | OR, 2.90 (1.20–7.50) | ( |
| 37/17 | bladder cancer | OR, 2.50 (1.04–6.10) | ( | ||||
| Turati | meta-analysis | 2014 | Italy | 3657/5962 | bladder cancer | RR, 0.92 (0.77–1.09) | ( |
| Boice | case-control study | 1995 | USA | 528/2628 | breast cancer | OR, 1.08 (0.87–1.30) | ( |
| Koenig | case-control study | 1991 | USA | 398/790 | breast cancer | OR, 0.80 (0.60–1.10) | ( |
| Cook | case-control study | 1999 | USA | 315/393 | breast cancer | RR, 1.10 (0.90–1.30) | ( |
| 204/138 | breast cancer | RR, 1.90 (1.40–2.50) | ( | ||||
| Zheng | case-control study | 2002 | USA | 608/609 | breast cancer | OR, 0.90 (0.70–1.20) | ( |
| Nasca | case-control study | 1992 | USA | 1617/1617 | breast cancer | OR, 1.04 (0.90–1.21) | ( |
| Heikkinen | case-control study | 2015 | Finland | 6567/21598 | breast cancer | OR, 1.23 (1.11–1.36) | ( |
| Petro-Nustas | case-control study | 2002 | Jordan | 100/100 | breast cancer | OR, 8.62 (3.33–22.28) | ( |
| Eberle | prospective study | 2019 | USA | NA | breast cancer | HR, 1.45 (1.10–1.90) | ( |
| Nasca | case-control study | 1980 | USA | 118/233 | breast cancer | OR, 4.50 (1.20–15.78) | ( |
| Gera | meta-analysis | 2018 | UK | NA | breast cancer | RR, 1.19 (1.03–1.37) | ( |
| Xu | meta-analysis | 2021 | China | NA | breast cancer | OR, 1.07 (1.01–1.13) | ( |
| Grodstein | prospective study | 1994 | USA | NA | hematopoietic cancer | RR, 0.90 (0.70–1.20 | ( |
| non-Hodgkin’s lymphoma | RR, 1.10 (0.80–1.60) | ||||||
| Hodgkin’s lymphoma | RR, 0.90 (0.40–2.10) | ||||||
| multiple myeloma | RR, 0.40 (0.20–0.90) | ||||||
| Miligi | case-control study | 1999 | Italy | 165/828 | Hodgkin’s lymphoma | OR, 0.70 (0.50–1.10) | ( |
| 134/828 | multiple myeloma | OR, 0.80 (0.50–1.20) | |||||
| 260/828 | leukemia | OR, 0.90 (0.70–1.30) | |||||
| Benavente | case-control study | 2005 | Spain | 574/616 | hematopoietic cancer | OR, 1.20 (0.90–1.70) | ( |
| Tavani | case-control study | 2005 | Italy | 446/1295 | non-Hodgkin’s lymphoma | OR, 1.03 (0.73–1.44) | ( |
| 158/1295 | Hodgkin’s lymphoma | OR, 0.68 (0.40–1.18) | |||||
| 141/1295 | multiple myeloma | OR, 1.17 (0.70–1.97) | |||||
| Wong | case-control study | 2010 | USA | 649/1298 | non-Hodgkin’s lymphoma | OR, 0.93 (0.75–1.16) | ( |
| Zahm | case-control study | 1992 | USA | 385/1432 | non-Hodgkin’s lymphoma | OR, 1.50 (1.10–2.20) | ( |
| 70/1432 | Hodgkin’s lymphoma | OR, 1.70 (0.70–4.00) | |||||
| 72/1432 | multiple myeloma | OR, 1.80 (0.90–3.70) | |||||
| 56/1432 | leukemia | OR, 1.00 (0.30–2.60) | |||||
| Zhang | case-control study | 2009 | USA | 601/717 | follicular lymphoma | OR, 1.90 (1.10–3.30) | ( |
| non-Hodgkin’s lymphoma | OR, 1.30 (1.00–1.80) | ( | |||||
| Zhang | case-control study | 2009 | USA | 4461/5799 | non-Hodgkin’s lymphoma | OR, 1.30 (1.10–1.40) | ( |
| Guo | case-control study | 2009 | USA | 261/247 | non-Hodgkin’s lymphoma | OR, 1.46 (1.10–1.95) | ( |
| 132/177 | OR, 1.03 (0.75–1.42) | ||||||
| Cantor | case-control study | 1988 | USA | 622/1245 | non-Hodgkin’s lymphoma | OR, 2.00 (1.30–3.00) | ( |
| Herrinton | interview study | 1994 | USA | women | multiple myeloma | OR, 1.00 (0.70–1.40) | ( |
| men | OR, 1.50 (0.75–2.90) | ||||||
| Koutros | case-control study | 2009 | USA | 175/679 | multiple myeloma | OR, 0.80 (0.50–1.10) | ( |
| Mele | case-control study | 1995 | Italy | 254/1161 | leukemia | OR, 1.50 (0.60–3.70) | ( |
| Cantor | case-control study | 1988 | USA | 578/1245 | leukemia | OR, 1.80 (1.10–2.70) | ( |
| Chen | case-control study | 2006 | USA | 272/418 | testicular germ cell tumor | OR, 1.50 (1.00–2.20) | ( |
| 83/180 | OR, 1.70 (1.00–2.80) | ||||||
| 189/238 | OR, 1.70 (1.10–2.60) |
33/12 and 37/17 indicate subjects with the NAT2 slow acetylation phenotype and those with the CYP1A2 slow phenotype, respectively.
315/393 and 204/138 indicate subjects using the single hair dye method and those using two or more methods, respectively.
261/247 and 132/177 indicate subjects using hair dye before 1980 and those using hair dye in and after 1980, respectively.
272/418, 83/180, and 189/238 indicate all children, boys, and girls, respectively. Abbreviations: OR, odds ratio; RR, relative ratio; HR, hazard ratio.